This is an old revision of this page, as edited by Innerstream (talk | contribs) at 13:49, 24 December 2024 (new page). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 13:49, 24 December 2024 by Innerstream (talk | contribs) (new page)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compoundIdentifiers | |
---|---|
IUPAC name
| |
CAS Number | |
PubChem CID | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C15H19N3OS |
Molar mass | 289.40 g·mol |
3D model (JSmol) | |
SMILES
|
Butamisole is a pharmaceutical drug used in veterinary medicine. It is an anthelmintic of the imidazothiazole class. In dogs it is used for the treatment of infections with whipworms such as Trichuris vulpis and with hookworm such as Ancylostoma caninum. It acts as a nicotinic acetylcholine receptor agonist that causes sustained muscle contraction in the parasite followed by depolarizing neuromuscular blockade which leads to paralysis.
References
- B. T. Alford, G. T. Wang, T. R. Garces, R. B. Dougherty, R. E. Bradley (1979). "The efficacy and safety of injectable butamisole in dogs". Veterinary Medicine & Small Animal Clinician. 74 (4): 487–495.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - . doi:10.1016/S1090-0233(05)80005-X.
{{cite journal}}
: Cite journal requires|journal=
(help); Missing or empty|title=
(help) - ^ "Butamisole". Inxight Drugs. National Center for Advancing Translational Sciences.